The Role of Next Generation Sequencing Panels in Personalized Medicine of Lung Cancer: A Review Study

Lung cancer is one of the leading causes of death globally, affecting both men and women with a high mortality rate. The majority of cases are diagnosed at an advanced stage, contributing to its poor prognosis. Early detection is crucial but challenging due to the asymptomatic nature of early-stage disease. Identifying reliable tumor markers is vital for improving diagnosis. Next-generation sequencing (NGS) has revolutionized oncology by offering detailed insights into the genetic makeup of lung cancer. NGS allows for comprehensive genomic profiling, even from small samples, identifying mutations, gene fusions, and copy number variations. This review explores the role of NGS panels in lung cancer's early detection, particularly within personalized medicine. NGS enables clinicians to detect actionable biomarkers, tailor treatments based on individual genomic profiles, and improve outcomes. Its ability to analyze multiple genes simultaneously makes it efficient in identifying therapeutic targets and resistance mechanisms. Additionally, NGS processes large datasets quickly, promoting its adoption in clinical practice. By identifying genetic mutations driving tumor development, NGS supports more precise treatment approaches, improving clinical management and reducing mortality. Its cost-effectiveness, particularly in reducing the need for multiple tests, strengthens its position in oncology. As personalized medicine advances, NGS is expected to play a key role in lung cancer's diagnosis, prognosis, and treatment, with ongoing technological improvements enhancing its clinical utility.

کلیدواژه ها:

Next Generation Sequencing ، biomarker ، Early diagnosis